AANPCB Board Prep/Assess
๐Ÿ”Ž

Assess

Comprehensive psychiatric evaluation, mental status exam, risk assessment, screening instruments, and collateral information gathering.

219 questions ยท AANPCB: 33% of exam
What the AANPCB tests in Assessโ–ถ

The Assess domain accounts for 33% of scored questions on the AANPCB PMHNP-C exam โ€” the single largest domain. It tests whether you can gather the right information before making clinical decisions: performing comprehensive psychiatric evaluations, conducting mental status exams, completing risk assessments, ordering appropriate screening instruments and labs, and gathering collateral information.

Questions in this domain present clinical scenarios where the correct answer involves knowing what to assess, not what to do about it. You may need to identify the most appropriate screening instrument for a presenting complaint, determine which laboratory tests to order to rule out organic causes, or recognize which elements of a psychiatric history are most relevant to the clinical picture.

The AANPCB specifically tests assessing readiness for change and barriers to care โ€” motivational interviewing concepts applied to the assessment process. Social determinants of health, cultural factors, and developmental considerations all appear as Assess-domain questions.

Practice Assess Questions

Build a custom quiz and track your performance across all four AANPCB process domains. Free account required.

Build a Quiz

All 219 questions

1.
Mental Status Exam Findings in Psychosis
intermediatemental status examinationthought processpsychosis
โ†’
2.
Serotonin Pathways and the Neuroscience of Depression
intermediateserotonindepressionmonoamine hypothesis
โ†’
3.
Dopamine Hypothesis of Schizophrenia and Antipsychotic Mechanisms
intermediatedopamineschizophreniaantipsychotics
โ†’
4.
GABAergic Mechanisms in Anxiety and Benzodiazepine Pharmacology
beginnerGABAanxietybenzodiazepines
โ†’
5.
HPA Axis Dysregulation and the Stress Response
advancedHPA axiscortisolCRH
โ†’
6.
PHQ-9 Item 9 and Suicide Risk Screening
beginnerPHQ-9suicide screeningpatient safety
โ†’
7.
AUDIT-C Positive Screen for Unhealthy Alcohol Use
intermediateAUDIT-Calcohol screeningsubstance use
โ†’
8.
MDQ Bipolar Screening: Interpretation and Limitations
intermediateMDQbipolar screeningscreening tools
โ†’
9.
MI and Stages of Change: Identifying Contemplation
beginnermotivational interviewingstages of changeTranstheoretical Model
โ†’
10.
Yalom's Therapeutic Factors in Group Therapy
advancedgroup therapyYalomtherapeutic factors
โ†’
11.
Epigenetics and Adverse Childhood Experiences
intermediateepigeneticsadverse childhood experiencesDNA methylation
โ†’
12.
Sleep Architecture Stages and Psychiatric Implications
intermediatesleep architectureREM latencyslow-wave sleep
โ†’
13.
Blood-Brain Barrier and Drug Lipophilicity
beginnerblood-brain barrierlipophilicitypharmacokinetics
โ†’
14.
Kindling Model in Bipolar Disorder Progression
intermediatekindlingbipolar disordermood stabilizer
โ†’
15.
Competency vs Capacity: Clinical and Legal Distinctions
intermediatecapacitycompetencydecision-making
โ†’
16.
Boundary Violations vs Boundary Crossings in Therapeutic Relationships
beginnerboundariesboundary crossingboundary violation
โ†’
17.
Behavioral Interventions in Intellectual Disability
intermediateintellectual disabilityfunctional behavioral assessmentbehavioral interventions
โ†’
18.
Military Sexual Trauma Screening in Veterans
intermediatemilitary sexual traumaveteranVA
โ†’
19.
Transgender Patient Mental Health Assessment
intermediatetransgendergender dysphoriaminority stress
โ†’
20.
Refugee and Immigrant Trauma: Cultural Considerations in Assessment
advancedrefugeecultural competenceidioms of distress
โ†’
21.
Mentalization-Based Treatment for Borderline Personality Disorder
advancedmentalization-based treatmentborderline personality disordermentalization
โ†’
22.
Structural Family Therapy: Boundaries and Subsystems
advancedstructural family therapyMinuchinboundaries
โ†’
23.
Norepinephrine Pathways and the Locus Coeruleus in Anxiety
intermediatenorepinephrinelocus coeruleusPTSD
โ†’
24.
Endocannabinoid System and Psychiatric Relevance
advancedendocannabinoid systemCB1 receptorcannabis
โ†’
25.
Oxytocin and Social Bonding in Attachment Disorders
intermediateoxytocinattachmentsocial bonding
โ†’
26.
Inflammatory Cytokines and the Neuroinflammation Hypothesis of Depression
intermediateneuroinflammationcytokinesIDO
โ†’
27.
Default Mode Network and Rumination in Depression
advanceddefault mode networkruminationdepression
โ†’
28.
Reward Prediction Error and Dopamine Signaling in Addiction
advancedreward prediction errordopamineaddiction
โ†’
29.
Fear Conditioning and Extinction in Amygdala-Prefrontal Circuits
advancedfear conditioningextinctionamygdala
โ†’
30.
Hypothalamic-Pituitary-Gonadal Axis and Mood in Perimenopause
intermediateHPG axisestradiolperimenopause
โ†’
31.
Tolerance and Sensitization as Neuroadaptive Processes in Substance Use
intermediatetolerancesensitizationneuroadaptation
โ†’
32.
Capacity Evaluation for Psychiatric Treatment Refusal
advancedcapacity assessmentAppelbaum criteriatreatment refusal
โ†’
33.
Cultural Competence as an Ethical Obligation in Psychiatric Care
intermediatecultural competenceCultural Formulation InterviewDSM-5-TR
โ†’
34.
Intellectual Disability and Psychiatric Comorbidity Assessment
intermediateintellectual disabilitydiagnostic overshadowingcomorbidity
โ†’
35.
Transgender Patients: Psychiatric Assessment Considerations
intermediatetransgendergender dysphoriaWPATH
โ†’
36.
Veterans: Military Sexual Trauma Assessment and Treatment
intermediatemilitary sexual traumaMSTveterans
โ†’
37.
Adolescent Non-Suicidal Self-Injury: Assessment and Risk
intermediateNSSIadolescentself-injury
โ†’
38.
Deaf and Hearing-Impaired Patients: Communication and Assessment
intermediateDeaf patientsASL interpreterADA
โ†’
39.
Burnout and Compassion Fatigue: Self-Care as Professional Duty
beginnerburnoutcompassion fatigueMaslach
โ†’
40.
Therapeutic Factors and Group Cohesion
advancedgroup therapyYalomtherapeutic factors
โ†’
41.
Capacity Assessment for a Patient Refusing Antipsychotic Medication
intermediatecapacity assessmentAppelbaum criteriaappreciation
โ†’
42.
HPA Axis Dysregulation in PTSD
intermediateHPA axisPTSDcortisol
โ†’
43.
Glutamate NMDA Receptor Hypofunction in Schizophrenia
intermediateglutamateNMDA receptorschizophrenia
โ†’
44.
Epigenetics and the Impact of Early Adversity on Gene Expression
beginnerepigeneticsearly adversityACEs
โ†’
45.
Substance Use Screening in Adolescents Using SBIRT
beginneradolescentsubstance useSBIRT
โ†’
46.
Psychotropic Prescribing Principles in Intellectual Disability
advancedintellectual disabilitydiagnostic overshadowingpsychotropic prescribing
โ†’
47.
Transgender Mental Health and Gender-Affirming Assessment
intermediatetransgendergender-affirming careminority stress model
โ†’
48.
Cultural Humility in Psychiatric Assessment
beginnercultural humilityCultural Formulation InterviewDSM-5
โ†’
49.
Medication Reconciliation During Transitions of Care
beginnermedication reconciliationtransitions of carepatient safety
โ†’
50.
Thyroid Hormone Dysregulation and Psychiatric Symptom Mimicry
beginnerthyroidhypothyroidismdepression
โ†’
51.
Circadian Rhythm Neurobiology and Mood Disorder Pathophysiology
intermediatecircadian rhythmsuprachiasmatic nucleusbipolar disorder
โ†’
52.
Neurodevelopment: Prefrontal Cortex Maturation and Adolescent Risk-Taking
beginnerneurodevelopmentprefrontal cortexadolescent brain
โ†’
53.
Psychiatric Genetics: Heritability and Polygenic Risk Architecture
intermediategeneticsheritabilitypolygenic risk
โ†’
54.
The Gut-Brain Axis: Enteric Serotonin and Microbiome-CNS Communication
intermediategut-brain axisserotoninmicrobiome
โ†’
55.
G-Protein Coupled Receptors and Second Messenger Signal Transduction
advancedGPCRsecond messengercAMP
โ†’
56.
Anxiety and Alcohol Use โ€” Temporal Relationship Assessment
intermediateanxietyalcohol usesubstance-induced anxiety
โ†’
57.
Depression Medical Mimics and Bipolar Screening
intermediatedepressionhypothyroidismbipolar screening
โ†’
58.
First-Episode Mania โ€” Substance Use Screening
intermediatemaniafirst episodesubstance-induced
โ†’
59.
Delirium vs Late-Onset Psychosis in Elderly Patient
intermediatedeliriumelderlyopioids
โ†’
60.
PTSD and Trauma Assessment in Combat Veteran
intermediatePTSDcombat veterantrauma assessment
โ†’
61.
Eating Disorder Medical Stability Assessment
intermediateanorexia nervosaeating disordersmedical stability
โ†’
62.
Depression in Alcohol Use Disorder Recovery
advanceddepressionalcohol use disorderprotracted withdrawal
โ†’
63.
Panic Disorder Differential Beyond Cardiac Workup
intermediatepanic disorderdifferential diagnosisagoraphobia
โ†’
64.
ADHD Multi-Informant Assessment in Children
intermediateADHDpediatricVanderbilt
โ†’
65.
Bipolar Depression on Lamotrigine โ€” Reassessment Before Adjusting
advancedbipolar IIlamotriginebipolar depression
โ†’
66.
First-Episode Psychosis โ€” Medical and Substance Workup
intermediatefirst-episode psychosisUDSautoimmune encephalitis
โ†’
67.
SSRI Sexual Dysfunction โ€” Differential Assessment
intermediateSSRIsexual dysfunctionfluoxetine
โ†’
68.
Grief-Related Hallucinations โ€” Normal vs Pathological
intermediategriefbereavementhallucinations
โ†’
69.
NSSI Risk Assessment in BPD with Acute Stressor
advancedNSSIBPDsuicide risk assessment
โ†’
70.
Chronic Insomnia โ€” Shift Work and Modifiable Factors
intermediateinsomniashift work disordercaffeine
โ†’
71.
ODD Differential โ€” Underlying Conditions in Children
intermediateODDADHDlearning disabilities
โ†’
72.
Clozapine Comprehensive Monitoring
advancedclozapineREMSANC monitoring
โ†’
73.
Social Anxiety Disorder vs GAD Differentiation
intermediatesocial anxiety disorderGADcomorbidity
โ†’
74.
Tardive Dyskinesia โ€” AIMS Assessment
intermediatetardive dyskinesiaAIMShaloperidol
โ†’
75.
Postpartum Depression vs Psychosis โ€” Ego-Dystonic Thoughts
advancedpostpartum depressionpostpartum psychosisego-dystonic
โ†’
76.
Early SSRI Response โ€” Assessment and Suicide Risk Window
intermediateSSRIearly responsesuicidal ideation
โ†’
77.
Racing Thoughts Differential โ€” Bipolar vs ADHD vs Anxiety
intermediateracing thoughtsbipolarADHD
โ†’
78.
Cognitive Decline in Elderly โ€” Reversible Causes Workup
intermediatecognitive declinedementiapseudodementia
โ†’
79.
Adolescent Mood Lability โ€” Avoiding Premature Diagnostic Labeling
intermediateadolescentmood labilityself-harm
โ†’
80.
Valproate Hepatotoxicity โ€” Systematic Assessment
advancedvalproatehepatotoxicityliver enzymes
โ†’
81.
Suicide Risk Assessment After Attempt โ€” Disposition Decision
advancedsuicide riskC-SSRSdisposition
โ†’
82.
Medical Etiology Indicators vs Primary MDD with Comorbid GAD
intermediatemedical etiologysubstance-induced mood disorderPHQ-9
โ†’
83.
Lithium Toxicity โ€” Assessment and Drug Interactions
advancedlithium toxicitydrug interactionsrenal function
โ†’
84.
ADHD Screening โ€” Informant Discordance in a Child
intermediateADHDVanderbiltinformant discordance
โ†’
85.
Atypical Depression โ€” Symptom Pattern Recognition
intermediateatypical depressionDSM-5 specifierbipolar II
โ†’
86.
MSE โ€” Differentiating Mania from Delirium
advancedMSEmaniadelirium
โ†’
87.
Anticholinergic Burden โ€” Visual Hallucinations in Elderly
advancedanticholinergic burdenACB scalepolypharmacy
โ†’
88.
Adult ADHD Evaluation โ€” Comprehensive Assessment Approach
intermediateADHDadultASRS
โ†’
89.
Metabolic Lab Interpretation โ€” Antipsychotic-Induced Metabolic Syndrome
intermediatemetabolic syndromequetiapineHbA1c
โ†’
90.
Bulimia Nervosa โ€” Expected Lab Findings
intermediatebulimia nervosahypokalemiametabolic alkalosis
โ†’
91.
Prolactin Elevation โ€” Risperidone-Induced Galactorrhea
intermediateprolactinrisperidonegalactorrhea
โ†’
92.
Alcohol Withdrawal โ€” CIWA-Ar Assessment and Monitoring
advancedalcohol withdrawalCIWA-Ardelirium tremens
โ†’
93.
Conduct Disorder โ€” Differential Assessment in Adolescent
intermediateconduct disorderadolescentASPD
โ†’
94.
Venlafaxine-Induced Hypertension โ€” Dose-Dependent Effect
intermediatevenlafaxineSNRIhypertension
โ†’
95.
OCD โ€” Intact Insight as Differentiator from Psychotic Disorder
intermediateOCDinsightego-dystonic
โ†’
96.
Parkinson's Disease Psychosis โ€” Medication-Induced Assessment
advancedParkinson's diseasepramipexoledopamine agonist
โ†’
97.
Substance-Induced vs Primary Psychotic Disorder โ€” Differentiation
intermediatesubstance-induced psychosiscannabisschizophrenia
โ†’
98.
Pre-ECT Assessment โ€” Cardiac and Anesthesia Risk
advancedECTtreatment-resistant depressionpre-procedure assessment
โ†’
99.
Serotonin Syndrome Differentiation from Expected SSRI Side Effects
intermediateserotonin syndromeSSRIsertraline
โ†’
100.
Separation Anxiety Disorder โ€” Pediatric Presentation
intermediateseparation anxietypediatricschool refusal
โ†’
101.
Delusional Disorder, Persecutory Type โ€” Differentiation from Schizophrenia
intermediatedelusional disorderpersecutory typeschizophrenia
โ†’
102.
PMDD โ€” Prospective Daily Mood Charting for Diagnosis
intermediatePMDDprospective chartingluteal phase
โ†’
103.
QTc Prolongation โ€” Citalopram in Elderly Patient
advancedQTc prolongationcitalopramgeriatric
โ†’
104.
CRAFFT โ€” Adolescent Substance Use Screening Tool
intermediateCRAFFTadolescentsubstance use
โ†’
105.
NSAID-Lithium Interaction โ€” Acute Toxicity and Emergency Management
advancedlithium toxicityNSAID interactionibuprofen
โ†’
106.
Treatment-Resistant Depression โ€” Verification Before Ketamine
intermediatetreatment-resistant depressionketamineadequate trial
โ†’
107.
Lithium Nephrotoxicity โ€” Rising Creatinine at Therapeutic Level
advancedlithiumnephrotoxicitycreatinine
โ†’
108.
Illness Anxiety Disorder โ€” Differentiating from Panic and SSD
intermediateillness anxiety disorderhypochondriasispanic disorder
โ†’
109.
Neuroleptic Malignant Syndrome โ€” Emergency Assessment
advancedNMSneuroleptic malignant syndromeantipsychotic
โ†’
110.
Pediatric OCD Severity Assessment โ€” CY-BOCS Dimensions
intermediateOCDpediatricCY-BOCS
โ†’
111.
Globus Sensation โ€” Somatic Symptom Assessment After Negative Workup
intermediatesomatic symptom disorderglobus sensationillness anxiety disorder
โ†’
112.
Depression in OUD Recovery โ€” Temporal Relationship Assessment
intermediateOUDbuprenorphinedepression
โ†’
113.
Provisional Tic Disorder โ€” Comorbidity Screening in Pediatrics
intermediatetic disorderTourette'sprovisional tics
โ†’
114.
Somatic Symptom Burden โ€” PHQ-15 and Trauma Screening
intermediatesomatic symptom disorderPHQ-15ACEs
โ†’
115.
Valproate Hyperammonemic Encephalopathy at Therapeutic Level
advancedvalproatehyperammonemiaencephalopathy
โ†’
116.
Anorexia Nervosa vs ARFID โ€” Body Image Assessment
intermediateanorexia nervosaARFIDbody image
โ†’
117.
Serotonin Syndrome โ€” Duloxetine and Tramadol Interaction
advancedserotonin syndromeduloxetinetramadol
โ†’
118.
Grief vs MDD After Miscarriage โ€” PHQ-9 Limitations
intermediategriefMDDPHQ-9
โ†’
119.
Donepezil-Oxybutynin Anticholinergic Conflict in Dementia
intermediatedonepeziloxybutyninanticholinergic
โ†’
120.
Adolescent Depression Screening โ€” PHQ-A Selection
intermediateadolescent depressionPHQ-Ascreening tools
โ†’
121.
SSRI-Aspirin Bleeding Interaction โ€” Platelet Aggregation
intermediateSSRIaspirinbleeding
โ†’
122.
Geriatric Fall Risk โ€” Beers Criteria and Medication Review
intermediateBeers Criteriafall riskbenzodiazepine
โ†’
123.
Adult ADHD โ€” Age-of-Onset as Key Differentiator
intermediateADHDadultage of onset
โ†’
124.
Low TSH with Residual Symptoms โ€” Lab Interpretation
intermediateTSHhyperthyroidismlab interpretation
โ†’
125.
DMDD vs ODD โ€” Inter-Episode Irritability Differentiation
intermediateDMDDODDtantrums
โ†’
126.
Metabolic Syndrome Criteria โ€” Olanzapine Monitoring
intermediatemetabolic syndromeolanzapineschizophrenia
โ†’
127.
Kratom as Opioid-Receptor Substance โ€” Assessment
intermediatekratomopioid receptorUDS
โ†’
128.
Dementia Agitation โ€” Sundowning and Treatable Causes
intermediatedementiasundowningagitation
โ†’
129.
Breakthrough Mania โ€” Subtherapeutic Lithium and Nonadherence
intermediatebipolar disorderlithiumnonadherence
โ†’
130.
Sympathomimetic Toxidrome โ€” ED Assessment and Lab Priorities
advancedsympathomimetic toxidromestimulantsMDMA
โ†’
131.
CYP2D6 Polymorphism and Pharmacogenomic Variability
hardCYP2D6pharmacogenomicsfluoxetine
โ†’
132.
GABA-A Receptor Subtypes and Anxiolytic Selectivity
hardGABA-A receptorbenzodiazepinealpha subunit
โ†’
133.
Blood-Brain Barrier Permeability and Drug Lipophilicity
intermediateblood-brain barrierlipophilicityP-glycoprotein
โ†’
134.
Valproate Teratogenicity and Neural Tube Defect Risk in Pregnancy
hardpregnancyvalproateteratogenicity
โ†’
135.
Geriatric Anticholinergic Burden and Beers Criteria Application
intermediategeriatricanticholinergic-burdenbeers-criteria
โ†’
136.
Postpartum Depression Screening with the Edinburgh Postnatal Depression Scale
intermediatepostpartum-depressionEPDSscreening
โ†’
137.
Psychotropic Use Considerations in Intellectual Disability
hardintellectual-disabilitydiagnostic-overshadowingself-injurious-behavior
โ†’
138.
Transgender Patient Psychiatric Assessment and Minority Stress
hardtransgenderminority-stressgender-identity
โ†’
139.
Differentiating Delirium from Dementia in Geriatric Patients
intermediategeriatricdeliriumdementia
โ†’
140.
Medical Complications of Adolescent Eating Disorders and Refeeding Risk
hardeating-disordersanorexia-nervosarefeeding-syndrome
โ†’
141.
Perinatal Anxiety Management and Breastfeeding Medication Safety
intermediateperinatalbreastfeedinganxiety
โ†’
142.
Autism Spectrum Disorder and Co-occurring Psychiatric Conditions
hardautism-spectrum-disorderdepressiondiagnostic-overshadowing
โ†’
143.
Military/Veteran PTSD and Cultural Barriers to Treatment
intermediateveteransPTSDmilitary-culture
โ†’
144.
Panic Disorder with Agoraphobia Assessment
intermediatepanic disorderagoraphobiaanxiety disorders
โ†’
145.
Dissociative Identity Disorder Assessment Features
harddissociative identity disorderdissociationassessment
โ†’
146.
Catatonia Recognition and Assessment
hardcatatoniaschizophreniamalignant catatonia
โ†’
147.
Gambling Disorder Assessment and Screening
intermediategambling-disorderbehavioral-addictionscreening-tools
โ†’
148.
Norepinephrine Pathways and Anxiety Response
intermediatenorepinephrinelocus coeruleusanxiety
โ†’
149.
Cholinergic System and Cognitive Decline
intermediateacetylcholineAlzheimer's diseasenucleus basalis of Meynert
โ†’
150.
HLA-B*1502 Screening and Carbamazepine Risk
intermediatepharmacogenomicsHLA-B*1502carbamazepine
โ†’
151.
MSE Components โ€” Thought Process vs Thought Content
intermediatemental status examinationthought processthought content
โ†’
152.
Suicide Risk Assessment โ€” C-SSRS Ideation Intensity Subclassification
hardsuicide risk assessmentC-SSRSsuicidal ideation
โ†’
153.
Cognitive Screening โ€” MoCA vs MMSE Appropriateness
intermediatecognitive screeningMoCAMMSE
โ†’
154.
Assessing Medication Side Effects โ€” AIMS for Tardive Dyskinesia
intermediatetardive dyskinesiaAIMSantipsychotic side effects
โ†’
155.
Trauma-Informed Assessment โ€” Core Principles in Practice
intermediatetrauma-informed careassessment approachtherapeutic alliance
โ†’
156.
Cultural Formulation Interview โ€” Identifying Key Components
hardcultural formulation interviewDSM-5cultural assessment
โ†’
157.
Substance Use Severity Assessment โ€” AUDIT Interpretation
intermediateAUDITalcohol screeningsubstance use assessment
โ†’
158.
Pediatric Developmental Assessment โ€” Language Milestones
harddevelopmental assessmentpediatric milestonesjoint attention
โ†’
159.
Geriatric Depression Screening โ€” GDS Appropriateness and Interpretation
hardGDSgeriatric depressionscreening tools
โ†’
160.
Assessing Psychotic Symptoms โ€” Systematic Evaluation Approach
hardpsychotic symptomsfirst-episode psychosissystematic assessment
โ†’
161.
Pain Assessment in Psychiatric Patients โ€” Comorbid Considerations
hardpain assessmentdiagnostic overshadowingchronic pain
โ†’
162.
Functional Assessment and Disability Evaluation
hardfunctional assessmentdisability evaluationWHODAS
โ†’
163.
SSRI-Related Sexual Dysfunction Assessment
intermediatesexual-dysfunctionSSRIside-effects
โ†’
164.
Medical Stability in Eating Disorder Assessment
hardeating-disordersanorexia-nervosamedical-stability
โ†’
165.
Assessing for Neuroleptic Malignant Syndrome
hardNMSneuroleptic-malignant-syndromeserotonin-syndrome
โ†’
166.
Laboratory Workup for New-Onset Psychosis
intermediatepsychosisfirst-episodelaboratory-assessment
โ†’
167.
Combat-Related PTSD Assessment in Veterans
hardPTSDveteranscombat-trauma
โ†’
168.
Differentiating Akathisia from Restless Leg Syndrome
intermediateakathisiarestless-leg-syndromeantipsychotics
โ†’
169.
Cognitive Assessment in Early-Onset Dementia
harddementiafrontotemporal-dementiacognitive-assessment
โ†’
170.
Assessing Non-Suicidal Self-Injury in Adolescents
intermediateNSSIself-injuryadolescent
โ†’
171.
Assessing Malingering Versus Genuine Psychiatric Symptoms
hardmalingeringsymptom-validityforensic
โ†’
172.
Perinatal Mood and Anxiety Disorder Assessment
intermediateperinatalpostpartumOCD
โ†’
173.
Medication Interaction Assessment in Polypharmacy
hardpolypharmacydrug-interactionsCYP450
โ†’
174.
Sleep Disorder Assessment in Psychiatric Populations
intermediatesleep-disordersobstructive-sleep-apneadepression
โ†’
175.
Assessing Anticholinergic Toxicity Presentation
hardanticholinergic toxicitytoxidromemedication safety
โ†’
176.
Assessing Executive Function Deficits in Adult ADHD
hardADHDexecutive functionneuropsychological testing
โ†’
177.
Disaster Mental Health Triage Assessment
harddisaster mental healthtriagedissociative stupor
โ†’
178.
Assessing Serotonin Syndrome Clinical Features
hardserotonin syndromeneuroleptic malignant syndrometoxidrome
โ†’
179.
Assessing for Lithium Toxicity Signs
hardlithium toxicitydrug interactionthiazide diuretics
โ†’
180.
Violence Risk Assessment in Emergency Psychiatric Settings
hardviolence riskemergency psychiatrystructured professional judgment
โ†’
181.
Assessing Capacity for Informed Consent
harddecisional capacityinformed consentECT
โ†’
182.
Assessing Alcohol Withdrawal Severity Using CIWA-Ar
hardalcohol withdrawalCIWA-Arwithdrawal seizure
โ†’
183.
Assessing Opioid Withdrawal Using COWS Scale
intermediateopioid withdrawalCOWSbuprenorphine
โ†’
184.
Assessing Psychosis in the Context of Dementia
harddementiaAlzheimer's diseasepsychosis
โ†’
185.
Assessing for Factitious Disorder Imposed on Another
hardfactitious disorderMunchausen by proxypediatric assessment
โ†’
186.
Assessing Attention and Concentration in MSE
intermediatemental status examinationattentionconcentration
โ†’
187.
Psychotropic Medication Management in Renal Impairment
hardlithiumrenal-impairmentpharmacokinetics
โ†’
188.
Psychiatric Assessment of Deaf and Hard of Hearing Patients
harddeaf-communityASLcommunication-barriers
โ†’
189.
Geriatric Psychosis: Late-Onset Schizophrenia vs. Dementia-Related Psychosis
hardgeriatric-psychosislate-onset-schizophreniadementia
โ†’
190.
Foster Care Youth Psychiatric Assessment and Psychotropic Oversight
hardfoster-carepolypharmacycomplex-trauma
โ†’
191.
Psychiatric Assessment Following Traumatic Brain Injury
hardtraumatic-brain-injuryneuropsychiatryfrontal-lobe
โ†’
192.
Refugee and Asylum Seeker Mental Health Assessment
hardrefugeeasylum-seekercultural-competence
โ†’
193.
Behavioral Assessment in Intellectual Disability
intermediateintellectual-disabilitydental-painself-injurious-behavior
โ†’
194.
Adolescent Transgender Patient: Gender-Affirming Mental Health Assessment
hardtransgenderadolescentgender-dysphoria
โ†’
195.
Co-occurring Autism and Anxiety in Adults: Assessment Differentiation
hardautism-spectrum-disorderanxietyOCD
โ†’
196.
Assessing Benzodiazepine Withdrawal Seizure Risk
hardbenzodiazepine withdrawalseizure risksubstance withdrawal
โ†’
197.
Assessing Medication Reconciliation in Transitions of Care
hardmedication reconciliationtransitions of carelithium toxicity
โ†’
198.
Assessing for Drug-Induced Parkinsonism
harddrug-induced parkinsonismextrapyramidal symptomsantipsychotic side effects
โ†’
199.
Assessing Sexual Trauma Disclosure in Therapeutic Setting
hardtrauma assessmentPCL-5nonverbal communication
โ†’
200.
Assessing Stimulant Diversion Risk
hardstimulant diversionADHD assessmentASRS
โ†’
201.
Assessing for Antidepressant-Induced Hyponatremia
hardSIADHhyponatremiaSSRI adverse effects
โ†’
202.
Assessing Grief Versus Depression in Bereaved Patients
hardgriefbereavementmajor depressive disorder
โ†’
203.
Assessing for Steroid-Induced Psychiatric Symptoms
hardcorticosteroid-induced maniasubstance-induced bipolar disorderlupus
โ†’
204.
Assessing QTc Prolongation Risk Before Prescribing
hardQTc prolongationtorsades de pointescardiac safety
โ†’
205.
Assessing for Fetal Alcohol Spectrum Disorder
hardfetal alcohol spectrum disorderFASDADHD differential
โ†’
206.
Assessing Treatment Compliance Using Objective Measures
hardmedication adherencetherapeutic drug monitoringlithium
โ†’
207.
Assessing for Somatization in Emergency Settings
moderatesomatizationpanic disorderemergency assessment
โ†’
208.
Differentiating Acute Intoxication from Psychiatric Emergency
hardsubstance intoxicationtoxidromepsychiatric emergency
โ†’
209.
Assessing Pseudoseizures vs Epileptic Seizures
hardPNESpseudoseizuresconversion disorder
โ†’
210.
Geriatric Psychopharmacology and Reduced Hepatic Clearance
hardgeriatric-pharmacologyhepatic-metabolismphase-I-phase-II
โ†’
211.
Psychiatric Care Barriers in Incarcerated Populations
hardincarcerated-populationsforensic-psychiatrymedication-discontinuation
โ†’
212.
Sundown Syndrome Assessment in Elderly Patients
hardsundowningdementiaAlzheimer-disease
โ†’
213.
Social Media Impact on Adolescent Mental Health
hardsocial-mediaadolescent-mental-healthbody-image
โ†’
214.
Minority Stress Model in LGBTQ+ Youth Assessment
hardminority-stressLGBTQ-youthtransgender
โ†’
215.
Chronic Pain and Psychiatric Comorbidity in Elderly Patients
hardchronic-paingeriatric-depressionsuicide-risk
โ†’
216.
Acculturative Stress in First-Generation Immigrants
hardacculturative-stressimmigrationcultural-formulation
โ†’
217.
Assessing Polydipsia and Water Intoxication in Psychiatric Patients
hardpolydipsiawater intoxicationhyponatremia
โ†’
218.
Assessing Cognitive Decline in Chronic Schizophrenia
hardcognitive declineschizophrenianeuropsychological testing
โ†’
219.
Assessing Chronic Pain and Opioid Use Disorder Comorbidity
hardopioid use disorderchronic paintolerance
โ†’

Other AANPCB domains

๐Ÿงฉ Diagnose (21%)๐Ÿ“ Plan (26%)๐Ÿ“Š Evaluate (20%)

Want to understand the full AANPCB blueprint? Read the complete AANPCB exam guide โ†’

โ† AANPCB Board Prep